Related Experiment Video
Updated: Apr 18, 2026
07:31
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
4.5K
Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma
Vincent I Poon1, Michael Roth1, Sajida Piperdi1
1Division of Pediatric Hematology/Oncology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, 3415 Bainbridge Ave, Rosenthal Pavilion, Room 300, Bronx, NY 10467 USA.
Clinical Sarcoma Research
|February 3, 2015
Summary
Ganglioside GD2 is consistently expressed in osteosarcoma, even upon recurrence. This persistence suggests anti-GD2 antibody therapy may be effective for recurrent pediatric osteosarcoma.
Area of Science:
- Oncology
- Immunology
- Pediatric Medicine
Background:
- Osteosarcoma is a prevalent bone cancer in children and young adults.
- Ganglioside GD2 is a cell surface marker found in several tumor types, including osteosarcomas.
Purpose of the Study:
- To assess the expression of ganglioside GD2 in osteosarcoma tissues.
- To determine if GD2 expression persists in recurrent osteosarcoma.
Main Methods:
- Immunohistochemistry was used to evaluate GD2 expression.
- Forty-nine osteosarcoma samples from 14 patients were analyzed.
Main Results:
- GD2 was expressed in 47 out of 49 assessed osteosarcoma samples.
- GD2 expression was consistently detected in tissues from initial biopsy and recurrence in matched patient samples.
Conclusions:
- Ganglioside GD2 expression persists in osteosarcoma upon recurrence.
- The consistent GD2 expression supports further investigation of anti-GD2 antibody efficacy in a phase 2 trial for recurrent pediatric osteosarcoma.
